StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research note issued to investors on Sunday morning. The firm issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Price Performance
The firm has a market capitalization of $820,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a 12 month low of $0.61 and a 12 month high of $24.20. The stock’s fifty day simple moving average is $10.56 and its 200-day simple moving average is $11.97. The company has a current ratio of 0.33, a quick ratio of 0.26 and a debt-to-equity ratio of 3.07.
Acorda Therapeutics Company Profile
Read More
- Five stocks we like better than Acorda Therapeutics
- What is a SEC Filing?
- AMD is Down 35%. Now is the Time to Buy the Dip
- The 3 Best Retail Stocks to Shop for in August
- Amazon Stands Tall: New Highs Are in Sight
- Basic Materials Stocks Investing
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.